Compare
MapLight Therapeutics, Inc. vs Rhythm Pharmaceuticals, Inc. vs Enliven Therapeutics, Inc. vs Theravance Biopharma, Inc.
| Latest fiscal year | MapLight Therapeutics, Inc. MPLT | Rhythm Pharmaceuticals, Inc. RYTM | Enliven Therapeutics, Inc. ELVN | Theravance Biopharma, Inc. TBPH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $189.76M | n/a | $107.46M |
| Revenue growth (YoY) | n/a | +45.8% | n/a | +66.9% |
| Gross margin | n/a | 89.7% (computed) | n/a | n/a |
| Operating margin | n/a | -101.2% | n/a | -3.4% |
| Net margin | n/a | -103.6% | n/a | 98.5% |
| Net income | -$161.15M | -$196.54M | -$103.69M | $105.89M |
| EPS (Diluted) | -$18.56 | -$3.11 | -$1.83 | $2.06 |
| Operating cash flow | -$138.14M | -$115.67M | -$70.30M | $238.54M |
| Free cash flow | -$138.61M | -$116.63M | -$70.46M | $238.50M |
| Cash & equivalents | $46.73M | $54.30M | $98.90M | $167.81M |
| Total assets | $479.51M | $480.20M | $476.17M | $485.57M |
| Total liabilities | $21.14M | $210.17M | $16.57M | n/a |
| Shareholders' equity | $458.37M | $139.07M | $459.60M | $296.72M |
| Return on year-end equity | -35.2% | -141.3% | -22.6% | 35.7% |
| Shares outstanding | 44.02M | 67.21M | 59.44M | 51.07M |
Revenue, most recent five fiscal years
| Fiscal year | MapLight Therapeutics, Inc. | Rhythm Pharmaceuticals, Inc. | Enliven Therapeutics, Inc. | Theravance Biopharma, Inc. |
|---|---|---|---|---|
| Latest | n/a | $189.76M Ended 2025-12-31 | n/a | $107.46M Ended 2025-12-31 |
| 1 year earlier | n/a | $130.13M Ended 2024-12-31 | n/a | $64.38M Ended 2024-12-31 |
| 2 years earlier | n/a | $77.43M Ended 2023-12-31 | n/a | $57.42M Ended 2023-12-31 |
| 3 years earlier | n/a | $23.64M Ended 2022-12-31 | n/a | $51.35M Ended 2022-12-31 |
| 4 years earlier | n/a | $3.15M Ended 2021-12-31 | n/a | $55.31M Ended 2021-12-31 |